Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Notes Payables: 2021-2024

  • Summit Therapeutics' Notes Payables fell 75.50% to $24.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $24.5 million, marking a year-over-year decrease of 75.50%. This contributed to the annual value of $19.8 million for FY2022, which is N/A change from last year.
  • According to the latest figures from Q3 2024, Summit Therapeutics' Notes Payables is $24.5 million, which was down 75.50% from $100.0 million recorded in Q2 2024.
  • In the past 5 years, Summit Therapeutics' Notes Payables ranged from a high of $100.0 million in Q3 2023 and a low of $19.8 million during Q4 2022.
  • Its 3-year average for Notes Payables is $61.1 million, with a median of $62.2 million in 2023.
  • Data for Summit Therapeutics' Notes Payables shows a maximum YoY plummeted of 75.50% (in 2024) over the last 5 years.
  • Summit Therapeutics' Notes Payables (Quarterly) stood at $55.0 million in 2021, then reached $19.8 million in 2022, then reached $100.0 million in 2023, then crashed by 75.50% to $24.5 million in 2024.
  • Its Notes Payables stands at $24.5 million for Q3 2024, versus $100.0 million for Q2 2024 and $100.0 million for Q3 2023.